Bipolar disorder

BullFrog AI Announces Availability of Fireside Chat Recording Featuring CEOs of BullFrog AI and the Lieber Institute

Retrieved on: 
Venerdì, Marzo 8, 2024

GAITHERSBURG, Md., March 08, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced the availability of the recording for the recently held fireside chat.

Key Points: 
  • GAITHERSBURG, Md., March 08, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced the availability of the recording for the recently held fireside chat.
  • This enlightening session, hosted by RedChip Companies on March 5, 2024, featured BullFrog AI's CEO, Vin Singh, alongside Daniel R. Weinberger M.D., Director and CEO of the Lieber Institute for Brain Development (LIBD).
  • The recording can be accessed via the following link: https://youtu.be/40rogXtHBJ8
    The fireside chat provided a deep dive into the early findings from the collaboration between BullFrog AI and LIBD.
  • This innovative method has uncovered biological differences and similarities across various brain disorders and has identified potential biological subtypes within individual disorders.

Voya Financial expands its workplace benefits offerings with new supplemental health insurance solution

Retrieved on: 
Mercoledì, Febbraio 21, 2024

Voya Financial, Inc. (NYSE: VOYA), announced today that it continues to enhance its growing portfolio of workplace benefits by offering an innovative, technology-enabled solution to help employees ease the burden of out-of-pocket medical costs.

Key Points: 
  • Voya Financial, Inc. (NYSE: VOYA), announced today that it continues to enhance its growing portfolio of workplace benefits by offering an innovative, technology-enabled solution to help employees ease the burden of out-of-pocket medical costs.
  • Voya Protect, a new Group Limited Benefit Insurance powered by the insurance technology company Ansel Health, is a supplemental health offering that is designed to pay benefits quickly and easily when covered conditions are diagnosed.
  • And, while many employers have made changes to their benefit lineups to help support their employees, the reality is that workplace benefits are complex,” explained Nate Black, vice president, Health Solutions Product at Voya Financial.
  • Voya Protect is the latest example of how Voya is focused on providing innovative solutions and capabilities to help employers and their employees optimize their workplace benefits and savings needs.

Fierce Healthcare Names Talkiatry a "Fierce 15" Company of 2024

Retrieved on: 
Martedì, Febbraio 20, 2024

NEW YORK, Feb. 20, 2024 /PRNewswire/ -- Talkiatry, a leading provider of high-quality, in-network psychiatric care, announced today that Fierce Healthcare has named it one of 2024's "Fierce 15" healthcare companies. The annual special report features the most innovative private healthcare companies looking to change the face of the industry. 

Key Points: 
  • NEW YORK, Feb. 20, 2024 /PRNewswire/ -- Talkiatry, a leading provider of high-quality, in-network psychiatric care, announced today that Fierce Healthcare has named it one of 2024's "Fierce 15" healthcare companies.
  • The annual special report features the most innovative private healthcare companies looking to change the face of the industry.
  • "It's an honor to be featured in the 'Fierce 15' list with so many other visionary healthcare leaders," said Robert Krayn, co-founder and CEO, Talkiatry.
  • "For the past six years, we have assessed hundreds of private companies for inclusion in the 'Fierce 15' special report.

Orlando Health and Acadia Healthcare Hold Groundbreaking Ceremony for New Behavioral Health Hospital to Serve Greater Orlando Area

Retrieved on: 
Giovedì, Febbraio 15, 2024

Orlando Health and Acadia Healthcare today held a ceremony to celebrate the start of construction on a previously announced 144-bed behavioral health hospital that will expand access to critical mental health services in the Orlando metro area.

Key Points: 
  • Orlando Health and Acadia Healthcare today held a ceremony to celebrate the start of construction on a previously announced 144-bed behavioral health hospital that will expand access to critical mental health services in the Orlando metro area.
  • View the full release here: https://www.businesswire.com/news/home/20240215860586/en/
    Orlando Health and Acadia Healthcare Break Ground on Construction of a New Behavioral Health Hospital in Apopka, Florida, with an anticipated opening in Spring 2025.
  • “This hospital will expand Orlando Health’s existing capabilities and provide greater access to life-saving behavioral health services,” Chris Hunter, Chief Executive Officer of Acadia Healthcare.
  • This hospital will extend Orlando Health’s legacy of providing quality behavioral health services to their patients.”
    Once the new hospital is fully operational, Orlando Health will transfer all inpatient behavioral health services from its South Seminole Hospital Campus.

Madison health-tech startup invests $1M to improve, simplify access to mental health treatment worldwide

Retrieved on: 
Martedì, Febbraio 13, 2024

MADISON, Wis. , Feb. 13, 2024 /PRNewswire/ -- RehabPath, one of Madison's fastest-growing startups, has taken a massive step forward in their pursuit to connect people with quality mental health and addiction treatment.

Key Points: 
  • MADISON, Wis. , Feb. 13, 2024 /PRNewswire/ -- RehabPath, one of Madison's fastest-growing startups, has taken a massive step forward in their pursuit to connect people with quality mental health and addiction treatment.
  • "Recovery.com is an inclusive, memorable and optimistic name that lends instant credibility and trust to these efforts.
  • While rehab or inpatient care is sometimes necessary for people struggling with mental health and substance use disorders, it's only one aspect of treatment in the life-long journey of recovery.
  • "When people hear the word 'rehab' they tend to think of a residential stay for addiction treatment.

BullFrog AI to Discuss Findings from its Collaboration with Lieber Institute for Brain Development in Fireside Chat Hosted by RedChip

Retrieved on: 
Venerdì, Febbraio 9, 2024

The fireside chat will delve into the early findings from BullFrog AI and LIBD’s collaboration which successfully stratified brain expression data, offering what may turn out to be unprecedented insights into psychiatric conditions.

Key Points: 
  • The fireside chat will delve into the early findings from BullFrog AI and LIBD’s collaboration which successfully stratified brain expression data, offering what may turn out to be unprecedented insights into psychiatric conditions.
  • For the first time, this partnership has enabled the clustering of subjects based on biological data alone, independent of their behavioral diagnoses.
  • This innovative method has uncovered biological differences and similarities across various brain disorders and has identified potential biological subtypes within individual disorders.
  • To participate in the fireside chat, please register at:

Talkiatry Named to the New York Digital Health 100 by Digital Health New York (DHNY)

Retrieved on: 
Martedì, Febbraio 6, 2024

NEW YORK, Feb. 6, 2024 /PRNewswire/ -- Talkiatry, a leading provider of high-quality, in-network psychiatric care, today announced that it has been named to the 2024 New York Digital Health 100 (DH100), a recognition that highlights the most exciting and innovative startups in New York. Digital Health New York (DHNY) publishes the annual list in conjunction with the New York Healthcare Innovation Report which takes an in-depth look at the investment trends, opportunities and challenges in the digital health sector.

Key Points: 
  • NEW YORK, Feb. 6, 2024 /PRNewswire/ -- Talkiatry , a leading provider of high-quality, in-network psychiatric care, today announced that it has been named to the 2024 New York Digital Health 100 (DH100), a recognition that highlights the most exciting and innovative startups in New York.
  • Digital Health New York (DHNY) publishes the annual list in conjunction with the New York Healthcare Innovation Report which takes an in-depth look at the investment trends, opportunities and challenges in the digital health sector.
  • "The digital health landscape in New York City is dynamic, and it's an honor to be recognized amongst our peers on the New York Digital Health 100 list for the second year in a row," said Robert Krayn, co-founder and CEO, Talkiatry.
  • "2024 marks the fifth year of the New York Digital Health 100 and in that time, the digital health ecosystem in New York has significantly grown and evolved," said Bunny Ellerin, co-founder and CEO, DHNY.

BioXcel Therapeutics Announces USPTO’s Allowance of Patent Application for Method of Treating Agitation in Alzheimer’s Disease Using Oromucosal Formulations of Dexmedetomidine

Retrieved on: 
Lunedì, Febbraio 5, 2024

NEW HAVEN, Conn., Feb. 05, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced that the United States Patent and Trademark Office (“USPTO”) has allowed U.S. Patent Application No. 17/496,470 with claims pertaining to a method of treating agitation in patients with Alzheimer’s disease using the oromucosal administration of 60 mcg of dexmedetomidine in a water-soluble dosage form. The broad claims encompass film formulations such as BXCL501 (sublingual dexmedetomidine), tablets, or wafers. The patent, when issued, is expected to have an expiration date of Dec. 29, 2037, subject to patent term adjustment (“PTA”), patent term extension (“PTE”), and terminal disclaimers.

Key Points: 
  • 17/496,470 with claims pertaining to a method of treating agitation in patients with Alzheimer’s disease using the oromucosal administration of 60 mcg of dexmedetomidine in a water-soluble dosage form.
  • The broad claims encompass film formulations such as BXCL501 (sublingual dexmedetomidine), tablets, or wafers.
  • The patent, when issued, is expected to have an expiration date of Dec. 29, 2037, subject to patent term adjustment (“PTA”), patent term extension (“PTE”), and terminal disclaimers.
  • The Company also announced that it has received an issue notification from the USPTO for U.S. Patent Application No.

Annovis Bio Announces the Filing of New Patent Application for Treatment of Mental Illnesses Expanding the Company’s Portfolio

Retrieved on: 
Martedì, Gennaio 30, 2024

MALVERN, Pa., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, announced the filing of a patent application covering the use of buntanetap and its analogues for the treatment of neuropsychiatric indications.

Key Points: 
  • MALVERN, Pa., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, announced the filing of a patent application covering the use of buntanetap and its analogues for the treatment of neuropsychiatric indications.
  • Provisional Application No.
  • The patent application titled “Treatment of Mental Illness via Administration of Buntanetap and Analogues Thereof” addresses methods for treating, inhibiting, reducing, slowing, or delaying onset of mental illnesses by administration of buntanetap or its pharmaceutically acceptable salts.
  • Buntanetap can be used alone or synergistically with effective quantities of antipsychotic agents, antidepressant agents, hallucinogenic agents, or combinations thereof.

Precautionary measures to address potential risk of neurodevelopmental disorders in children born to men treated with valproate medicines

Retrieved on: 
Domenica, Febbraio 4, 2024

On 24 January 2024, the CMDh1 endorsed precautionary measures recommended by EMA’s safety committee (PRAC) for the treatment of male patients with valproate medicines. These…

Key Points: 


On 24 January 2024, the CMDh1 endorsed precautionary measures recommended by EMA’s safety committee (PRAC) for the treatment of male patients with valproate medicines. These…